Routine

Tobacco dependence & smoking cessation

treatable addiction · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Tobacco dependence is a chronic relapsing condition and the leading modifiable cause of respiratory disease. Combining behavioural support with pharmacotherapy substantially increases quit rates; every healthcare contact is an opportunity to intervene.

Red flags

  • Severe depression or suicidal ideation during cessation
  • Unstable cardiovascular disease (time pharmacotherapy appropriately)
  • Pregnancy (prefer behavioural support +/- NRT under guidance)
  • Seizure history (caution with bupropion)

Assessment

Differential diagnosis

  • Nicotine dependence (cigarettes)
  • Dual use with vaping/e-cigarettes
  • Smokeless tobacco use
  • Cannabis co-use
  • Coexisting mental-health/substance disorder affecting cessation

Investigations

  • Smoking history and dependence assessment (e.g. time to first cigarette)
  • Exhaled carbon monoxide measurement
  • Assessment of comorbidities and mental health
  • Medication review for interactions (smoking induces some drug metabolism)
  • Readiness and prior quit-attempt history

Management

  • Ask about tobacco use at every contact and document it
  • Advise quitting clearly and personalise the respiratory health benefits
  • Assess dependence, readiness to quit and prior attempts
  • Offer behavioural support / referral to a stop-smoking service (very brief advice at minimum)
  • Offer pharmacotherapy to all dependent smokers wishing to quit
  • Set a quit date and combine behavioural support with medication
  • Consider combination nicotine replacement (patch plus short-acting) for higher dependence
  • Discuss e-cigarettes as a harm-reduction aid for those who cannot quit with licensed therapy
  • Review drug doses affected by stopping smoking (e.g. theophylline, clozapine, warfarin)
  • Arrange follow-up, relapse prevention and re-treatment of relapses without judgement

Drugs & doses

Nicotine replacement: patch 21 mg/24 h plus a short-acting form (gum 2-4 mg / lozenge / inhalator) as needed
Varenicline 0.5 mg PO daily titrated to 1 mg twice daily (start 1-2 weeks before quit date, 12 weeks)
Bupropion 150 mg PO daily for 3 days then twice daily (start before quit date)
Cytisine where available as an alternative course

Disposition

Stop-smoking service referral; integrate into every respiratory encounter; proactive relapse follow-up.

Complications & pitfalls

  • Relapse
  • Nicotine-withdrawal symptoms (irritability, craving, low mood)
  • Weight gain
  • Drug-level changes on stopping smoking (e.g. clozapine, theophylline toxicity)

Exam pearls

  • Combining a nicotine patch with a fast-acting form outperforms single-agent NRT
  • Smoking cessation is the only intervention proven to alter the natural history of COPD
  • Stopping smoking reduces clearance of clozapine and theophylline — monitor levels/doses
  • Relapse is part of the process; re-offer treatment rather than withdraw support

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.